A BET inhibitor was recently reported to downregulate basal and cytokine-simulated expression of complement components in cultured hepatocytes and humanized mice, and to reduce activated complement C3 and C5 levels in the circulation of cardiovascular disease patients61. Here, C5 is linked to cardiovascular disorder.